Results found: 3

Number of results on page

Search results

Sort By:

Limit search:

Teraźniejszość i przyszłość leków biologicznych w terapii nowotworów głowy i szyi

100%

Pawłowska E., Dziadziuszko R., Narożny W.

Otorynolaryngologia - przegląd kliniczny

2018

vol. 17

issue 1

1-14

According to European Medicines Agency’s definition, biological agents are pharmaceuticals whose active substance is made by a living organism. Biologics modulate immunological response by mimicking endogenous proteins or interacting with signaling pathways. The vast majority of biologics used in oncology are monoclonal antibodies. Use of four biologics in treatment of head and neck cancers - cetuximab, afatinib, pembrolizumab, nivolumab, is supported by National Comprehensive Cancer Network (NCCN) and National Institute for Health and Care Excellence (NICE) guidelines. In Poland only cetuximab can be applied in everyday practice, with some limitations. Cetuximab should be administered concurrently with radical radiotherapy to patients with contraindications for cisplatin. Due to rapid development of immunotherapy and biologics in the last decades there are currently hundreds of clinical trials conducted, seeking for most optimal regimens of biological drugs in head and neck cancer treatment, both in radical treatment (neoadjuvant and adjuvant therapy or in combination with radiotherapy) and in paliative treatment (in monotherapy, in combination with chemotherapeutic agents or other biological agents).

Zgodnie z definicją Europejskiej Agencji Leków leki biologiczne są farmaceutykami, których substancja aktywna wytwarzana jest przez żyjący organizm. Mechanizm ich działania polega na modulacji reakcji immunologicznych poprzez naśladowanie naturalnie występujących cząsteczek lub interakcji z ich szlakiem molekularnym. Największą grupę leków biologicznych stanowią przeciwciała monoklonalne. Cztery leki biologiczne zostały zaaprobowane przez zagraniczne towarzystwa onkologiczne (amerykańską Narodową Sieć Ośrodków Onkologicznych NCCN oraz Narodowy Instytut Zdrowia i Doskonałości Klinicznej Wielkiej Brytanii NICE) do terapii nowotworów płaskonabłonkowych głowy i szyi – cetuksymab, afatynib, pembrolizumab i niwolumab. W Polsce tylko pierwszy z nich jest dostępny w codziennej praktyce klinicznej, we wskazaniach ograniczonych ministerialnym programem lekowym. Kwalifikują się do niego chorzy poddawani radykalnej radioterapii, z przeciwwskazaniami do cisplatyny. Gwałtowny rozwój immunoterapii i leczenia celowanego w ostatnich dekadach sprawił, że obecnie toczą się setki badań klinicznych oceniających skuteczność leków biologicznych w terapii nowotworów rejonu głowy i szyi zarówno w leczeniu radykalnym (neoadjuwantowo, adjuwantowo lub w skojarzeniu z radioterapią) jak i paliatywnym (w monoterapii, skojarzeniu z chemioterapeutykami lub innymi lekami biologicznymi).

Panel of serum metabolites discriminates cancer patients and healthy participants of lung cancer screening - a pilot study

64%

Roś-Mazurczyk M., Wojakowska A., Marczak Ł., Polański K., Pietrowska M., Polanska J., Dziadziuszko R., Jassem J., Rzyman W., Widlak P.

2017

vol. 64

issue 3

513-518

Introduction. Blood biomarkers may support early diagnosis of lung cancer by enabling pre-selection of candidates for computed tomography screening or discrimination between benign and malignant screening-detected nodules. We aimed to identify features of serum metabolome distinguishing individuals with early-detected lung cancer from healthy participants of the lung cancer screening program. Methods. Blood samples were collected in the course of a low-dose computed tomography screening program performed in the Gdansk district (Northern Poland). The analysis included 31 patients with screening-detected lung cancer and the pair-matched group of 92 healthy controls. The gas chromatography coupled to mass spectrometry (GC/MS) approach was used to identify and quantify small metabolites present in serum. Results. There were several metabolites detected in the sera whose abundances discriminated patients with lung cancer from controls. Majority of the differentiating components were downregulated in cancer samples, including amino acids, carboxylic acids and tocopherols, whereas benzaldehyde was the only compound significantly upregulated. A classifier including nine serum metabolites allowed separation of cancer and control samples with 100% sensitivity and 95% specificity. Conclusions. Signature of serum metabolites discriminating between cancer patients and healthy participants of the early lung cancer screening program was identified using a GC/MS metabolomics approach. This signature, though not validated in an independent dataset, deserves further investigation in a larger cohort study.

Identification of serum proteome components associated with progression of non-small cell lung cancer

52%

Pietrowska M., Jelonek K., Michalak M., Roś M., Rodziewicz P., Chmielewska K., Polański K., Polańska J., Gdowicz-Kłosok A., Giglok M., Suwiński R., Tarnawski R., Dziadziuszko R., Rzyman W., Widłak P.

2014

vol. 61

issue 2

325-331

The aim of the present study was to perform comparative analysis of serum from patients with different stages of non-small cell lung cancer (NSCLC) using the three complementary proteomic approaches to identify proteome components associated with the progression of cancer. Serum samples were collected before any treatment from 200 patients with NSCLC, including 103 early stage, 64 locally advanced and 33 metastatic cancer samples, and from 200 donors without malignancy. The low-molecular-weight fraction of serum proteome was MALDI-profiled in all samples. Serum proteins were characterized using 2D-PAGE and LC-MS/MS approaches in a representative group of 30 donors. Several significant differences were detected between serum samples collected from patients with early stage cancer and patients with locally advanced cancer, as well as between patients with metastatic cancer and patients with local disease. Of note, serum components discriminating samples from early stage cancer and healthy persons were also detected. In general, about 70 differentiating serum proteins were identified, including inflammatory and acute phase proteins already reported to be associated with the progression of lung cancer (serum amyloid A or haptoglobin). Several differentiating proteins, including apolipoprotein H or apolipoprotein A1, were not previously associated with NSCLC. No significant differences in patterns of serum proteome components were detected between patients with adenocarcinoma and squamous cell carcinoma. In conclusion, we identified the biomarker candidates with potential importance for molecular proteomic staging of NSCLC. Additionally, several serum proteome components revealed their potential applicability in early detection of the lung cancer.

Refine search results

2 Acta Biochimica Polonica

1 Otorynolaryngologia - przegląd kliniczny

1 2018

1 2017

1 2014

3 Dziadziuszko R.

2 Pietrowska M.

2 Polański K.

2 Rzyman W.

1 Chmielewska K.

1 Gdowicz-Kłosok A.

1 Giglok M.

1 Jassem J.

1 Jelonek K.

1 Marczak Ł.

1 Michalak M.

1 Narożny W.

1 Pawłowska E.

1 Polanska J.

1 Polańska J.

1 Rodziewicz P.

1 Roś M.

1 Roś-Mazurczyk M.

1 Suwiński R.

1 Tarnawski R.

1 Widlak P.

1 Widłak P.

1 Wojakowska A.

Search results

Teraźniejszość i przyszłość leków biologicznych w terapii nowotworów głowy i szyi

Panel of serum metabolites discriminates cancer patients and healthy participants of lung cancer screening - a pilot study

Identification of serum proteome components associated with progression of non-small cell lung cancer